Loading...

Annual Conference 2012

3rd Harvard Chinese Life Science Research Symposium

April 28-29, 2012

 Children’s Hospital Boston, Dana-Farber Cancer Institute, Boston

Taking discoveries to new frontier through compassion and collaboration

HMS CSSA, HSPH CSSA, ACMA

Register: http://harvardchineselifescience.eventbrite.com/

Free event, light lunch provided, seats limited. Register soon!

 

Featured Speakers:

  • Prof. Laisheng Chou, Director of Division of Oral Medicine, Boston University School of Dental Medicine
  • Dr. Haijun Dong, COO, Lilly China R&D Company
  • Prof. Xinhua Feng, Dean of Life Science Institute, Zhejiang University
  • Prof. Xi He, Children’s Hospital Boston, Harvard Medical School
  • Dr. Jason Jin, CEO, Shanghai Biochip Corporation
  • Dr. Peter Li, CEO and President, Nexcelom Bioscience
  • Prof. Xihong Lin, Department of Biostatistics, Harvard School of Public Health
  • Prof. Jun Liu, Department of Biostatistics, Harvard School of Public Health
  • Prof. Xiao Le Liu, Dana-Faber Cancer Institute, Harvard Medical School
  • Dr. Yuanli Liu, Director of China Initiative Program, Harvard School of Public Health
  • Dr. Jiping Wang, Associate Director of Hepatobiliary Program, Brigham and Women’s Hospital
  • Dr. Ye Yin, VP, Beijing Genomics Institute
  • Dr. Junying Yu, Senior Director, Cellular Dynamics International 
  • Dr. Wenru Song, Millennium, The Takeda Oncology Company

Printable Flyer and Agenda Here

Symposium Flyer
Harvard Symposium Tentative Agenda(Updated!)

Saturday, April 28th 2012

 

9:00am-9:25am Registration

 

9:25am-9:30am Opening Remarks

Dr. Wenyu Song

President, HMS-CSSA

 

Session 1 Basic Biological Sciences

 

9:30am-10:00am Dr. Xi He

Professor, Children’s Hospital Boston, Harvard Medical School

“Understanding Wnt signaling and the Wnt morphogen In development and disease.”

 

10:00am-10:20am Dr. Yu Fu

Awarded Postdoc

“Unwinding mechanism of the eukaryotic replicative DNA helicase”

 

10:20am-10:40am Dr. Jian Xu

Awarded Postdoc

From Genetic Association to Genetic Switch

 

10:40am-11:10am Tea Break

 

11:10am-11:40am Dr. Xinhua Feng

Dean, Life Sciences Institute, Zhejiang University

Phosphatases in Signaling and Development.

 

11:40am-12:00pm Dr. Jun Ding

Awarded Postdoc

“Semaphorin 3E–Plexin-D1 signaling controls pathway-specific synapse formation in the striatum”

 

12:00pm-12:20pm Dr. Long-Jun Wu

Awarded Postdoc

“Proton channel in the brain: pH regulation and beyond”

 

12:20pm-12:25pm Postdoc Award-HMS

 

12:25pm-2:25pm Lunch break

 

2:25pm-2:55pm Dr. Xiaole Shirley Liu

Professor, Dana-Farber Cancer Institute, Harvard Medical School

“Computational Cancer Epigenetics.”

 

2:55pm-3:15pm Dr. Wei’an Zhao

Awarded Postdoc

“Development of Bioengineered Technologies for Targeting, Sensing and Detecting Cells”

 

3:15pm-3:35 pm Tea Break

 

Session 2 Public Health

 

3:35pm-3:40pm Introductory Remarks

Zhonghua Liu

President, HSPH -CSSA

 

3:40pm-4:10pm Dr. Jun Liu

Professor, Department of Biostatistics

Harvard School of Public Health

“Developments and Future Opportunities in Computational Biology”

 

4:10pm-4:40pm Dr. Xihong Lin

Professor, Department of Biostatistics

Harvard School of Public Health

“Design and Analysis of Whole Exome (Genome) Sequencing Association Studies.”

 

4:40pm-5:00pm Dr. An Pan

Awarded Postdoc

“Can depression increase your risk of stroke”

 

5:00pm-5:05pm Postdoc Award-HSPH

6:00pm-9:00pm Reception (Invitation only)

 

Sunday, April 29th 2012

 

Session 1 Public Health

 

10:00am-10:30am Dr. Yuanli Liu

Director, China Initiative, Harvard School of Public Health

“China’s Health Sector Development: Opportunities and Challenges.”

 

10:30am-10:50am Weixiong Ke

Awarded Fellow

“Patient sharing and population genetic structure of methicillin-resistant Staphylococcus aureus”

 

10:50am-10:55am Postdoc Award-HSPH

 

10:55am-11:15am Tea Break

 

Session 2 Translational Medicine

 

11:15am-11:45am Dr. Jiping Wang

Associate Director of Hepatobiliary Program

Division of Surgical Oncology, Brigham and Women’s Hospital, Harvard Medical School

“Translational Medicine: a clinician and biostatistician’s prospective.”

 

11:45am-12:15pm Dr. Laisheng Chou

Director, Division of Oral Medicine,

Boston University, School of Dental Medicine

Bone Tissue Engineering.

 

12:15pm-12:35pm Dr. Chunguang Guo

Awarded postdoc

“A master genetic control for the antibody repertoire”

 

12:35pm-12:40pm Postdoc Award-HMS

 

12:40pm-1:30pm Lunch

 

Session 3 Biotech Industry Outlook

 

1:30pm-2:00pm Dr. Haijun Dong

COO, Lilly China R&D Company

“Pharma China R&D Strategy: an Eli Lilly perspective, Returnees: Life and Career in China.”

 

2:00pm-2:30pm Dr. Junying Yu

“Person of the Year” for 2007 by the TIME magazine

Senior Director, Advance Development Programs

Cellular Dynamics International

“Human induced pluripotent stem cells: present and future.”

 

2:30pm-3:00pm Dr. Ye Yin

Vice President, Beijing Genomics Institute (BGI)

“Gene leads future.”

 

3:00pm-3:20pm Tea Break

 

3:20pm-3:50pm Dr. Jason Jin

CEO, Shanghai Biochip Corporation

“New International Collaboration Model in Translational Medicine: How Harvard researchers work together with collaborators in China”

 

3:50pm-4:20pm Dr. Peter Li

CEO and President, Nexcelom Bioscience

“From Technology to Business Success: An Entrepreneurial Perspective.”

 

4:20pm-4:50pm Dr. Wenru Song

Medical director, Millennium

“Millennium: Aspiring to Cure Cancer: From Targeted translational Medicine to Personalized Medicine”

 

4:50pm-4:55pm Closing Remarks

Dr. Chaoshe Guo

Co-President, HMS-CSSA

 

Speaker introduction

Xi He, PhD

Professor of Neurology, Children’s Hospital Boston and Harvard Medical School

Dr. Xi He received his PhD in 1992 from the University of California, San Diego, where he worked in the laboratory of Michael G. Rosenfeld. He completed a postdoctoral fellowship in 1996 at the National Institutes of Health, under the supervision of Harold E. Varmus. He was a Pew Scholar in Biomedical Sciences, a Klingenstein Fellow in Neuroscience, a Keck Foundation Distinguished Young Scholar in Medical Research and a Leukemia and Lymphoma Society Scholar. He is a Chang Jiang Guest Professor at the School of Life Science and Technology, Huazhong University of Science and Technology in Wuhan, China, inducted by the Ministry of Education of China.

Dr. Xi He focuses on molecular mechanisms that govern vertebrate embryogenesis and growth regulation, in particular the signaling mechanism employed by the Wnt family of secreted growth factors. He is a member of the executive board of the Stem Cell Program at Children’s Hospital Boston and a member of the editorial boards of Journal of Biological Chemistry, Journal of Genetics and Genomics and Protein & Cell. He has served and is serving on the Scientific Advisory Boards of institutes of the Chinese Academy of Sciences and of biotechnology companies in the United States, China and Europe.

Xinhua Feng, PhD

Professor, Dean, Life Science Institute, Zhejiang University.

Dr. Feng received his Bachelor’s Degree at Wuhan University in 1983, Master’s Degree at Chinese Academy of Sciences in 1986, and PhD degree at University of Maryland at College Park in 1992. After postdoctoral training at University of California,San Francisco, he received the position as an Assistant Professor in Department of Molecular & Cellular Biology, Baylor College of Medicine in 1999 and became a tenured Associate Professor in 2003. From 2009 to now, Dr. Feng is Professor and Dean of Life Science Institute, Zhejiang University, China.

Dr. Feng is a leading scientist in cancer research, focusing on the phosphatome in signaling and development. He received the Research Achievement Award of W.M. Keck Fndn Distinguished Young Scholars in Medical Research in 2001, Research Scholar Award of American Cancer Society in 2003, Michael E. DeBakey Research in Excellence Award, BCM in 2006, and Research in Excellence Award, BCM in 2007. He also received Joint Research Fund for Overseas Chinese, National Science Foundation of China in 2004 and was elected into “One Thousand Talents Scheme” of China in 2010.

Xiaole Shirley Liu, PhD

Associate Professor of Biostatics, Harvard School of Public Health

Dr. X. Shirley Liu is Professor of Biostatistics and Computational Biology at Harvard School of Public Health and Co-Director of the Center for Functional Cancer Epigenetics at the Dana-Farber Cancer Institute. Her research focuses on computational models of transcriptional and epigenetic regulation by algorithm development and data integration for high throughput data. She has developed a number of widely used transcription factor motif finding and ChIP-chip/Seq analysis algorithms, and has conducted pioneering research studies on gene regulation in development, metabolism, and cancers. Dr. Liu published 95 papers, including 27 in Nature, ScienceorCell, and has an H-index of 40.

Jun Liu, PhD.

Professor of Statistics, Professor of Biostatistics, Harvard University.

Dr. Liu Jun received his PhD in Statistics from University of Chicago and was appointed a full professor by Harvard University when he was 35. He received Morningside Gold Metal for Applied Mathematics for the outstanding mathematicians of Chinese descent under age 45, honored once every 3 years by ICCM in 2010. He received the 2002 COPSS Presidents’ Award given annually and jointly by five leading statistical societies in North America to a young individual (under age 40) in recognition of outstanding contributions to the profession of statistics. He is among the ISI most-cited mathematical scientists in 2003. He is a Fellow of American Statistical Association and Institute of Mathematical Statistics. He serves as the co-editor of Journal of American Statistical Association (JASA), and associate editors of other top journals in statistics.

Xihong Lin, PhD

Professor of Biostatistics, Co-ordinating Director, Program in Quantitative Genomics, Harvard School of Public Health.

Dr. Lin Xihong received her PhD from University of Washington in 1994, B.S. in Applied Mathematics from Tsinghua University in 1989. She is the leading statistician in the world and received numerous prestigious awards and honors. She received the COPSS Presidents’ Award for outstanding statistician in 2006 which is regarded as the “Nobel Prize” in statistics, the Mortimer Spiegelman Award for the Outstanding Biostatistician by American Public Health Association, the Janet L. Norwood Award for Outstanding Achievement of a Woman in Statistics, the Mentoring Award from Harvard School of Public Health, etc.

She is an elected Fellow of the American Statistical Association and Institute of Mathematical Statistics. She served as the Chair of Committee of the Presidents of Statistical Societies, 2010-1012. She is also the founding co-editor of Statistics in Biosciences, as well as an editor or associate editor of top journals in biostatistics and statistics.

Yuanli Liu, PhD, MPH

 

Senior Lecturer on International Health, Department of Global Health and Population; Director, China Initiative, Harvard School of Public Health

Dr. Liu received his BS and MPH degrees in medicine and public health from Tongji Medical University in 1987, MS in health policy and management from Harvard University in 1988, and PHD in health economics from the University of Minnesota in 1995.

Dr. Yuanli Liu is Senior Lecturer on International Health at the Department of Global Health and Population of Harvard School of Public Health. He is also Adjunct Professor of Health Policy and Management at Tsinghua University and director of the Health and Development Institute at Tsinghua School of Public Policy and Management in Beijing. Professor Liu has been teaching and conducting research in the areas of health policy and health system analysis since 1994 at Harvard, and has conducted extensive research and policy consultation work in many African and Asian countries. In particular, he has been closely involved in helping inform China’s policy making process for a series of reforms and strategic developments in its health sector since 1993, including the most recent work on Healthy Beijing 2020 – developing China’s first 10-year strategic plan for effectively combating diseases and improving population health. He serves on the Expert Committee of Health Policy and Management and the Expert Committee on Healthy China 2020, both of which are established by the Chinese Ministry of Health to help develop strategies for China to deal with major infectious as well as non-communicable diseases. In 2003 Harvard School of Public Health profiled six professors as “Future Leaders in Public Health”. Dr. Liu is one of them. Dr. Liu served as a coordinator of the Global Health Equity Initiative. He served on the United Nations Millennium Development Taskforce on HIV/AIDS, Malaria, TB, and Access to Basic Medicines. He served as a health policy and health system consultant to various international agencies including the World Bank, UNICEF, WHO, UNDP, and Asian Development Bank as well as Fortune 500 healthcare and pharmaceutical companies. Dr. Liu is also Vice-President of the China Foundation, Inc., a US-based non-profit organization.

Jiping Wang, MD, PhD

 

Associate Director of Hepatobilliary Cancer Program, Division of Surgical Oncology at Brigham and Women’s Hospital, Harvard Medical School and the Gastrointestinal Cancer Treatment Center at Dana-Farber Cancer Institute.

Dr. Wang received his PhD training in Biostatistics at University of Pittsburgh. He served as a biostatistician at National Surgical Adjuvant Breast and Bowel Project, where he participated in multiple phase III breast cancer clinical trials upon his graduation. During Dr. Wang’s surgical residency training at the State University of New York at Buffalo, he was appointed as an adjunct assistant professor in the Department of Biostatistics and a statistical consultant at Roswell Park Cancer Institute. He developed a unique statistical course for residents and fellows named “Anatomy of Biostatistics”. Subsequently, Dr. Wang obtained the Fineberg Fellowship to train at Brigham and Women’s Hospital, Massachusetts General Hospital and Dana Farber Cancer Institute.

Dr. Wang practices oncologic surgery with a focus on minimally-invasive cancer surgery for gastrointestinal malignancies including liver cancer, colorectal cancer, liver metastasis, pancreatic, gastric, colorectal cancer and neuroendocrine tumors.

Dr. Wang’s research focuses on identification of tumor markers for cancer screening, monitoring treatment effectiveness and prognosis; development of algorithms and/or scoring systems to guide clinical oncology research and practice, and clinical trials for cancer prevention and treatment. Dr. Wang has been involved in clinical research on breast and GI cancer for over 10 years. His research in oncology has received many national level awards including: ASCO Annual Meeting Merit Award (2008, 2010), ASCO Breast Cancer Symposium Merit Award (2007), Seed Grant from American Medical Association Foundation (2008) and AstraZeneca Scholar (2002). He also won the Leadership Scholarship from American College of Surgeons (ACS) 2008 and the scholarship from ASCO/AACR (2009). Dr. Wang serves as a committee member for multiple surgical societies including American College of Surgeons and Society for Surgery of Alimentary Tract.

Laisheng Chou, MD, PhD

Professor, Boston University School of Dental Medicine

Dr. Chou is currently the Professor and Director of Division of Oral Medicine, Professor of Biomaterials, and Director of Oral AIDS Clinic at Boston University.

Dr. Chou received his dental degree from Shanghai No. 2 Medical University, received both Diploma in Oral Pathology in 1988 and Diploma in Oral Medicine in 1989 from University of California, San Francisco, and received his PhD degree in Biology in 1997 from the University of British Columbia.

Dr Chou is a world-renowned expert on bone tissue engineering, molecular biocompatibility of implant materials, and HIV-associated oral lesions. He currently is working with Chinese collaborators to transform his patent-protected biomedical inventions, including one for scaffolds for bone tissue engineering into mass production.

Haijun Dong, PhD, MBA

Chief Operating Officer, Lilly (China) R&D Company, Limited, Eli Lilly and Company

Dr. Dong received his PhD in chemistry from the University of Washington, and MBA from China Europe International Business School. He cofounded two companies: Shanghai Jahwa Pharmaceuticals and IMPACT Therapeutics, Inc. and served as general manager and CEO of both of them, respectively. At Jahwa, he and his colleagues successfully completed a number of preclinical and clinical developments of generics and modified-release formulations, and received 12 clinical trial and final marketing approvals from the State Food and Drug Administration of China (SFDA). At IMPACT, his team discovered and patented several series of novel PARP-1 and Hedgehog pathway inhibitors as oncology medicines. Dr. Dong worked for Roche, both as a senior principal scientist in the US and as head of DMPK and Drug Safety in China, and for Boehringer Ingelheim, as a senior scientist in the US. He has coauthored a number of publications in journals such as JACS and DMD, as well as drug discovery patents. Dr. Dong is one of the “Leading Talents” selected globally by National Nanjing High and New Tech Zone and Nanjing University of Technology, and a winner of “Innovation and Entrepreneurship” by Jiangsu provincial government of China.

Junying Yu, PhD

Senior Director, Advance Development Programs

Cellular Dynamics International

Dr. Yu received her PhD in cell and molecular biology from the University of Pennsylvania in 2002. She graduated at the top of her class in 1997 from Peking University, Beijing, China, where she earned her B.S. in plant molecular and developmental biology.

Dr. Yu is one of the world’s leading experts in human induced pluripotent stem (iPS) cell technology, focusing on reprogramming adult cells to a fully pluripotent state and then differentiating them into any cell type in the body. In 2003 she joined the UW‐Madison lab of Dr. James Thomson, stem cell pioneer and the first to isolate human embryonic stem cells, and she has published 20 articles related to stem cell research. Her breakthrough research enables the creation of stem cells from any individual, thus driving forward regenerative medicine and personalized therapeutics, as well as circumnavigating the ethical issues surrounding embryonic stem cells. Dr. Yu, along with Thomson and Shinya Yamanaka, was recognized as a “Person of the Year” for 2007 by TIME magazine.

Ye Yin, PhD

Vice President, Beijing Genomics Institute (BGI)

Ye YiN, the former president of Research & Cooperation Division, is the present vice president of BGI and director of Genome Sequencing Operation. YiN has many achievements in scientific research and industry since he joined BGI in 2003. He has been involved in the fight against SARS, and in charge of declaring more than 20 diagnostic reagents of infectious diseases. He has also acted as the commander of “1000 Plant and Animal Reference Genomes project”, the leader of “One Million Human Genomes re-sequencing project”, the person in charge of “Mongolian plateau characteristic species genome project” and the project leader of “Mongolian genome project”. He guided many important international research projects such as the “asparagus genome project” and “grouper genome sequencing”. During that period, Yin has always kept good cooperative relationships with domestic and foreign experts in the life sciences, and has been invited to attend and address many international conferences, such as ICG and the PAG.

Jason JinPhD, MD

CEO, Shanghai Biochip Corporation

Dr. Jason (Gang) Jin is the Co-Founder and CEO of ShanghaiBio Corporation (SBC for global CRO at US), and Co-Founder and Executive VP for Global Business of Shanghai Biochip Co. Ltd (SBC in China), a leading biotech in China with lab operations in Shanghai and a global business office in New Jersey in U.S. Dr. Jin is also an adjunct professor at the Shanghai Institutes of Biological Sciences (SIBS), Chinese Academy of Sciences (CAS), and School of Pharmacy, Fudan University. Dr. Jin has extensive scientific and management experience in drug discovery and development. He has successfully developed and managed over 100 collaborative projects in genomics, pharmacogenomics, biomarkers, translational medicine, companion diagnostics to support discovery, pre-clinical research, and clinical trials with top global pharmaceutical and biotech companies in the past six years. He was recognized as one of the top 10 American-Chinese returnees by Business Week in 2008. Dr. Jin also received the top 10 American-Chinese Business Award in 2010 at US. Dr. Jin has held the former positions of Director of Genomics Lab at Purdue Pharma (USA), Director of Functional Genomics at Salk Institute (USA), Founder Director of National Engineering Center for Biochip at Shanghai (China), and radiologist at Shanghai Zhongshan Hospital (China). He received his PhD and postdoctoral training in biology from University of California, San Diego (USA), and his medical degree from School of Medicine, Fudan University (Shanghai Medical University, China). Dr. Jin also attended the intensive MBA class at Rutgers University.

Peter Y. Li, PhD

CEO, Nexcelom Bioscience

Dr. Li has extensive product development and business experience in large and small companies, where he has repeatedly contributed both as a technology inventor and as an effective leader to commercialize technology-driven products. While working at 3M, Eastman Kodak, SRU Biosystems, and Nexcelom Bioscience, he repeatedly took product ideas from invention and product design to production and commercialization. His past technical responsibilities included technical innovation, technology platform development, product design and testing, and manufacturing setup. With BS and PhD degrees in Physics from Peking University and Purdue University, Dr. Li became a productive innovator and prolific inventor with 33 issued US patents and more pending. He is a co-founder and CEO of Nexcelom Bioscience, which develops and markets Cellometer brand image-based cell counters and analysis systems for the life science market. Nexcelom Bioscience was honored as an Inc 500 Company in 2009, as one of the fastest growing private companies in America by Inc Magazine.

Wenru Song, MD, PhD

Medical director, Millennium

Dr. Song is a medical director at Millennium: The Takeda Oncology Company working in oncology drug clinical development and heading Millennium/Takeda’s oncology drug clinical development in Asia. Prior to join Millennium, Dr. Song was a medical director/clinical lead at Pfizer Oncology where he led a number of biologic compounds in the cancer immunotherapeutics and antibody-drug conjugate programs. Before joining the pharma-industry, he was an associate investigator at Baylor Institute of Immunology Research and an

attending oncologist physician at Texas Oncology/Baylor Sammons Cancer Center in Dallas. He studied Medicine in Shandong Medical University before coming to the US for his PhD study in Immunology. He then did his postdoctoral fellowship in cancer gene/immune therapy at Cornell University Medical Center, his medical residency at Montefiore Medical Center/Albert Einstein College of Medicine, and at Stanford University for his clinical oncology fellowship and research in cancer immunotherapy. Dr. Song is board-certified in medical oncology and internal medicine by the American Board of Internal Medicine.

Dr. Song’s clinical interest is on medical oncology, especially lymphoma, and his own lab research had been focused on the development of effective cancer immunotherapy. With the approval of three Investigational New Drug applications from the US FDA, he started to translate his lab research in cancer immunotherapy by initiating phase I/II human clinical trials in patients with colon or pancreatic cancer at Stanford University and in patients with lymphoma at Baylor Sammons Cancer Center in Dallas. Dr. Song has actively participated in community services and professional & scientific organizations, including as the founding board member and ex-board chair as well as the ex-president of the Chinese American Hematologist and Oncologist Network, an overseas member in the Executive Committee of Chinese Society of Clinical Oncology, a member of the Development Committee and the International Outreach Taskforce at the Society for Immunotherapy of Cancer, a member of Career Development Committee at American Society of Clinical Oncology, a member of the NCI’s Immune Response Modifier Pathway Prioritization Working Group, a member of the SITC-FDA-NCI Taskforce on Immunotherapy Biomarkers, and most recently as a member of World Immunotherapy Council.

 


Recipients of 2012 Harvard Chinese Life Science Research Award

 

Yu Fu, PhD

Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School

Jian Xu, PhD

Children’s Hospital Boston, Harvard Medical School

Jun Ding, PhD

Department of Neurobiology, Harvard Medical School.

LongJun Wu, PhD

Children’s Hospital Boston and Department of Neurobiology, Harvard Medical School.

Min Tang, PhD

Dana-Farber Cancer Institute and Harvard School of Public Health

Chunguang Guo, PhD

Immune Disease Institute, Children’s Hospital Boston and Harvard Medical School

Wei’an Zhao, PhD

Sue and Bill Gross Stem Cell Research Center, Chao Family Comprehensive Cancer Center and Department of Pharmaceutical Sciences at University of California

Xia Wang, PhD

Department of Cell Biology, Harvard Medical School

Changmeng Cai, PhD

Beth Israel Deaconess Medical Center, Harvard Medical School

Weixiong Ke, Master

Harvard School of Public Health

An Pan, PhD

Department of Nutrition Harvard School of Public Health

 

Sponsors

American Chinese Medical Association (ACMA)

北美中华医学会 www.acma.org

Establish ACMA as a premier American-Chinese medical and scientific organization. Function as a leader within the overseas Chinese medical community in establishing bridges to China.

BGI 华大基因 www.genomics.cn

BGI was founded in Beijing on Sept 9th, 1999 with the mission of supporting the development of science and technology, building strong research teams, and promoting the development of scientific partnership in genomics field.

Genscript www.genscript.com

GenScript is a leading biology CRO focusing exclusively on early drug discovery and development services, providing services that include Bio-Reagent, Bio-Assay, Lead Optimization, and Antibody Drug Development.

Nexcelom Bioscience

www.nexcelom.com

In 2003, the founders of Nexcelom introduced the CP2, a convenient tool to assist with manual cell counting. Nexcelom has expanded the product range to accommodate researchers analyzing small cells, primary cells, and researchers looking to perform cell-based assays.

ShanghaiBio 上海生物芯片有限公司

www.shanghaibio.com

ShanghaiBio Corporation performs specialty R&D services for global pharma/biotech companies. State-of-the-art labs provide GLP/GMP-compliant services and continually undergo rigorous internal and external QA audits.

Recruitment

 

Life Sciences Institute, Zhejiang University

浙江大学生命科学研究院

lsi.zju.edu.cn

The Life Sciences Institute (LSI) at Zhejiang University seeks 30 exceptional principal investigators at all ranks to conduct innovative research in broad areas of life sciences. Competitive start-up (≥5M RMB) and personal compensation (330K-800K plus housing) will be provided based on experience and research projects.

For details: http://hms-cssa.org/wp/p=379

Dear HMS-CSSA members,

As our tradition, Harvard Chinese Life Science Annual Distinguished Research Award is calling for competition! This prize will reward Chinese scientists whose research and discoveries were published in the last year and well recognized by scientific community. All scholars and scientists at Harvard Medical School and its affiliated hospitals and institutes are qualified and encouraged to participate.

Requirements and details:

1. Paper submitted for competition was published between January 1, 2011 and December 31, 2011.

2. Candidates of the competition should be one of major contributors of the submitted work.

3. Please send the paper, media report and a brief CV to cssa@hms-cssa.org by March 23, 2012. All documents should be in PDF format.

4. All submissions will be evaluated by the members of HMS-CSSA advisory board, who currently hold faculty positions at Harvard Medical School or MIT.

5. The result will be announced by HMS-CSSA at www.hms-cssa.org as well as by email before April 20, 2012.

6. Winners will have the opportunity to present their works at Harvard Chinese Life Science Annual Research Symposium

Please also tell your friends about this competition and encourage them to join us.

Thank you and have a nice weekend.

best

HMS-CSSA

http://hms-cssa.org/

Skip to toolbar